MDGL market cap is only $4.6B even with the $1.1B cash they have and they won't have competition in MASH for at least 3 yrs unless you count off label usage of Mounjaro/Tirzepatide.
Again, the market for MASH at this point for MASH specific compounds is not turning out to what many thought it would be. (I personally think the market has been overly bearish on MASH.)
Makes one wonder how they (and others) were able to raise so much cash recently.
News 
Market Data 
Discover 
